• Li-na Wang, Ming Yao, Jian-ping Yang, Jun Peng, Yan Peng, Cai-fang Li, Yan-bing Zhang, Fu-hai Ji, Hao Cheng, Qi-nian Xu, Xiu-yun Wang, and Jian-ling Zuo.
• Department of Anesthesiology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
• Mol Pain. 2011 Jul 1; 7: 4848.

BackgroundPrevious studies have demonstrates that, after nerve injury, extracellular signal-regulated protein kinase (ERK) activation in the spinal cord-initially in neurons, then microglia, and finally astrocytes. In addition, phosphorylation of ERK (p-ERK) contributes to nociceptive responses following inflammation and/or nerve injury. However, the role of spinal cells and the ERK/MAPK pathway in cancer-induced bone pain (CIBP) remains poorly understood. The present study analyzed activation of spinal cells and the ERK/MAPK pathway in a rat model of bone cancer pain.ResultsA Sprague Dawley rat model of bone cancer pain was established and the model was evaluated by a series of tests. Moreover, fluorocitrate (reversible glial metabolic inhibitor) and U0126 (a MEK inhibitor) was administered intrathecally. Western blots and double immunofluorescence were used to detect the expression and location of phosphorylation of ERK (p-ERK). Our studies on pain behavior show that the time between day 6 and day 18 is a reasonable period ("time window" as the remaining stages) to investigate bone cancer pain mechanisms and to research analgesic drugs. Double-labeling immunofluorescence revealed that p-ERK was sequentially expressed in neurons, microglia, and astrocytes in the L4-5 superficial spinal cord following inoculation of Walker 256 cells. Phosphorylation of ERK (p-ERK) and the transcription factor cAMP response element-binding protein (p-CREB) increased in the spinal cord of CIBP rats, which was attenuated by intrathecal injection of fluorocitrate or U0126.ConclusionsThe ERK inhibitors could have a useful role in CIBP management, because the same target is expressed in various cells at different times.

51 keywords...

hide…